OPA15406 a novel topical nonsteroidal selective phosphodiesterase4 PDE
- Slides: 6
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE 4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study Jon M. Hanifin, MD, Charles N. Ellis, MD, Ilona J. Frieden, MD, Regina Fölster-Holst, MD, Linda F. Stein Gold, MD, Angelo Secci, MD, Angela J. Smith, PA, Cathy Zhao, Ph. D, Elena Kornyeyeva, MD, Ph. D, Lawrence F. Eichenfield, MD Journal of the American Academy of Dermatology Volume 75 Issue 2 Pages 297 -305 (August 2016) DOI: 10. 1016/j. jaad. 2016. 04. 001 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Journal of the American Academy of Dermatology 2016 75297 -305 DOI: (10. 1016/j. jaad. 2016. 04. 001) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Journal of the American Academy of Dermatology 2016 75297 -305 DOI: (10. 1016/j. jaad. 2016. 04. 001) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Journal of the American Academy of Dermatology 2016 75297 -305 DOI: (10. 1016/j. jaad. 2016. 04. 001) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 Journal of the American Academy of Dermatology 2016 75297 -305 DOI: (10. 1016/j. jaad. 2016. 04. 001) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 5 Journal of the American Academy of Dermatology 2016 75297 -305 DOI: (10. 1016/j. jaad. 2016. 04. 001) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
